The biology and therapeutic targeting of the proprotein convertases
NG Seidah, A Prat - Nature reviews Drug discovery, 2012 - nature.com
The mammalian proprotein convertases constitute a family of nine secretory serine
proteases that are related to bacterial subtilisin and yeast kexin. Seven of these (proprotein …
proteases that are related to bacterial subtilisin and yeast kexin. Seven of these (proprotein …
[HTML][HTML] The PCSK9 decade: thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases
G Lambert, B Sjouke, B Choque, JJP Kastelein… - Journal of lipid …, 2012 - ASBMB
PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) is a crucial protein in LDL
cholesterol (LDL-C) metabolism by virtue of its pivotal role in the degradation of the LDL …
cholesterol (LDL-C) metabolism by virtue of its pivotal role in the degradation of the LDL …
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
N Ferri, G Tibolla, A Pirillo, F Cipollone, A Mezzetti… - Atherosclerosis, 2012 - Elsevier
OBJECTIVE: Proprotein convertase subtilisin kexin type 9 (PCSK9) is an important regulator
of hepatic low-density lipoprotein (LDL)-cholesterol levels. Although PCSK9 is mainly of …
of hepatic low-density lipoprotein (LDL)-cholesterol levels. Although PCSK9 is mainly of …
Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice
Background—The proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes
independently of its enzymatic activity the degradation of the low-density lipoprotein (LDL) …
independently of its enzymatic activity the degradation of the low-density lipoprotein (LDL) …
PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax–caspase9–caspase3 pathway
CY Wu, ZH Tang, L Jiang, XF Li, ZS Jiang… - Molecular and cellular …, 2012 - Springer
This paper investigated the effects of ox-LDL on PCSK9, and the molecular mechanisms of
PCSK9 siRNA-inhibited apoptosis induced by ox-LDL in human umbilical vein endothelial …
PCSK9 siRNA-inhibited apoptosis induced by ox-LDL in human umbilical vein endothelial …
Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial
BACKGROUND Although statin therapy is known to increase concentrations of PCSK9,
whether this effect is related to the magnitude of LDL reduction is uncertain. This study was …
whether this effect is related to the magnitude of LDL reduction is uncertain. This study was …
Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver
High circulating cholesterol is associated with hypercholesterolemia, atherosclerosis, and
stroke. However, the relation between cholesterol and tumorigenesis/metastasis is …
stroke. However, the relation between cholesterol and tumorigenesis/metastasis is …
[HTML][HTML] PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling
K Kysenius, P Muggalla, K Mätlik, U Arumäe… - Cellular and molecular …, 2012 - Springer
The secreted protease proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low-
density lipid (LDL) receptor family members LDLR, very low density lipoprotein receptor …
density lipid (LDL) receptor family members LDLR, very low density lipoprotein receptor …
Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia
M Abifadel, M Guerin, S Benjannet, JP Rabès… - Atherosclerosis, 2012 - Elsevier
BACKGROUND: The identification of mutations in PCSK9 (proprotein convertase subtilisin
kexin9) in autosomal dominant hypercholesterolemia (ADH), has revealed the existence of a …
kexin9) in autosomal dominant hypercholesterolemia (ADH), has revealed the existence of a …
[HTML][HTML] Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation
Proprotein convertase subtilisin/kexin-9 (PCSK9) enhances the degradation of hepatic low-
density lipoprotein receptor (LDLR). Deletion of PCSK9, and loss-of-function mutants in …
density lipoprotein receptor (LDLR). Deletion of PCSK9, and loss-of-function mutants in …